Skip to content

Outcomes of Full Pulpotomy Treatment in Teeth With Symptoms of Irreversible Pulpitis

Treatment Outcomes of Full Pulpotomy Using Two Different Calcium Silicate-based Materials in Mature Permanent Teeth With Irreversible Pulpitis Symptoms: A Randomized Clinical Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06802536
Enrollment
60
Registered
2025-01-31
Start date
2024-04-15
Completion date
2025-12-31
Last updated
2026-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulpitis - Irreversible

Keywords

irreversible pulpitis, calcium silicate-based cement, total pulpotomy

Brief summary

The aim of this clinical trial is to learn how successful Biodentine and NeoPutty dental filling materials are in treating dental pulp inflammation in adults. It will also provide information about post-treatment pain. The main questions it aims to answer are: Do Biodentine and NeoPutty dental filling materials treat dental pulpitis in participants? Do they reduce the need for root canal treatment? After the application of Biodentine and NeoPutty dental filling materials to the participants, the pain and symptoms that cause pain may not decrease. In this case, the tooth may be treated with root canal treatment. The researchers will compare the clinical success of Biodentine and NeoPutty dental filling materials with each other. Participants will undergo a single-session pulpotomy treatment with the dental filling materials mentioned above. Clinical and radiographic follow-ups will then be performed at 3, 6 and 12 months, and records will be kept.

Interventions

It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material.

DEVICENeoPutty (calcium silicate-based cement) (Avalon Biomed, Bradenton, USA)

It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material.

Sponsors

Firat University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Statistician

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* • Patient age must be between 18-50 years * Must be able to give written informed consent * Must have systemic status (ASA 1) * Must have mature permanent molar or premolar (lower upper) * Must be symptomatic (spontaneous pain - mild to severe), extremely deep (D4) carious teeth * Must have pulp exposure in non-selective carious cleaning procedure * Must have vital response in cold test and electric pulp test * Must have no periodontal disease * Must have restorable teeth * Must have teeth without pulp necrosis, sinus tract or swelling/abscess * Must have bleeding time less than 10 minutes * Maximum two teeth in a patient must be included in the study (must be in different quadrants and must have at least 2 weeks between treatment periods)

Exclusion criteria

* Teeth with incomplete root development * Teeth without symptoms of irreversible pulpitis * Severely affected teeth that do not respond to pulp sensitivity tests * Teeth without signs of bleeding after exposure with the pulp chamber * Teeth with pulp chamber open to the oral environment * Teeth with periodontal pockets greater than 4 mm deep * Teeth with suspected cracks or crown fractures that may be responsible for pulp pathology * Teeth with uncontrolled bleeding * Medically risky patients will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
"Tooth survival". Both clinical and radiographic healing means "Tooth survival". Clinical healing; absence of clinical symptoms. Radiographic healing; absence of emerging periapical radiolucency.From enrollment to the end of treatment at 1 year"

Secondary

MeasureTime frame
"Post operative pain". It will be evaluated with a 10-unit visual analog scale. 0: no pain, 1-3 mild pain, 4-6 moderate-severe pain, 7-9 very severe pain, 10 worst pain.From enrollment to the follow up at 1 week, 3,6.12 months"

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 5, 2026